Key result
Russian myocarditis guidelines face ongoing controversies in noninvasive diagnosis, biopsy indications, and immunosuppressive therapy.
Why the study?
Following the Russian clinical guidelines approved in October 2020, controversial and open issues in the management of myocarditis remained without unambiguous answers or unaddressed.
This expert commentary identifies unresolved issues in the 2020 Russian myocarditis guidelines to better guide clinical practice and inform future recommendations.
Controversies in Russian myocarditis guidelines warrant cautious clinical application; leaves open needs for standardized definitions and prospective validation.
In October 2020, the Russian Ministry of Health approved clinical guidelines for the management of patients with myocarditis. The aim of this review was to highlight controversial and open issues without unambiguous answer or those that were not described in the paper. The review highlights the objective factors that complicate the development of practical guidelines for the management of this category of patients. Comments on the definition and classification of inflammatory heart diseases are given. The approaches to the diagnosis of patients with suspected myocarditis are discussed. Particular attention is paid to the decision-making strategy in selecting optimal therapy in patients with documented myocarditis and the role of endomyocardial biopsy.
No takes yet. Share an insight, caveat, or question.
Благова et al. (2021) conducted a review in Myocarditis. Russian national recommendations for myocarditis was evaluated. Russian national guidelines for the management of myocarditis face ongoing controversies regarding disease definition, classification, noninvasive diagnosis, and indications for endomyocardial biopsy and immunosuppressive therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: